PharmaCyte Biotech, Inc. SEC filings PMCB
PharmaCyte Biotech, Inc. has 472 filings in SEC EDGAR's recent list, going back to Aug 20, 2001. Its latest annual report, Form 10-K, was filed on Jul 29, 2026 for the period ended Apr 30, 2026. The latest quarterly report (Form 10-Q) was filed on Sep 14, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (auditor change). The company's fiscal year ends on April 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Auditor change
|
Oct 16, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Sep 14, 2026 | Jul 31, 2026 |
| 10-K | Annual report | Jul 29, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Apr 2, 2026 | Mar 30, 2026 |
| 10-Q | Quarterly report | Mar 17, 2026 | Jan 31, 2026 |
| ARS | Annual report to shareholders | Mar 9, 2026 | Apr 30, 2025 |
| DEF 14A | Proxy statement | Mar 9, 2026 | Mar 30, 2026 |
| PRE 14A | Preliminary proxy statement | Feb 27, 2026 | Mar 30, 2026 |
| 10-Q | Quarterly report | Dec 18, 2025 | Oct 31, 2025 |
| NT 10-Q | Extension | Dec 15, 2025 | Oct 31, 2025 |
| 8-K |
Current report
Listing notice
|
Dec 5, 2025 | Dec 1, 2025 |
| 8-K/A | Amended current report | Nov 18, 2025 | Sep 2, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 31, 2025 | Oct 30, 2025 |
| DEF 14A | Proxy statement | Oct 6, 2025 | Oct 30, 2025 |
| EFFECT | Filing | Sep 26, 2025 | — |
| PRE 14A | Preliminary proxy statement | Sep 24, 2025 | Oct 30, 2025 |
| CORRESP | Letter to the SEC | Sep 24, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2025 | — |
| S-3 | Shelf registration | Sep 17, 2025 | — |
| 10-Q | Quarterly report | Sep 15, 2025 | Jul 31, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
|
Sep 5, 2025 | Sep 2, 2025 |
| D | Filing | Sep 4, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Aug 18, 2025 | Aug 17, 2025 |
| 10-K | Annual report | Aug 11, 2025 | Apr 30, 2025 |
| NT 10-K | Extension | Jul 29, 2025 | Apr 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Apr 24, 2025 | Apr 24, 2025 |
| 10-Q | Quarterly report | Mar 17, 2025 | Jan 31, 2025 |
| ARS | Annual report to shareholders | Mar 10, 2025 | Apr 30, 2024 |
| DEFA14A | Additional proxy material | Mar 10, 2025 | — |
| DEF 14A | Proxy statement | Mar 10, 2025 | Apr 24, 2025 |
| 8-K |
Current report
Auditor change
|
Feb 26, 2025 | Feb 21, 2025 |
| 10-Q | Quarterly report | Dec 13, 2024 | Oct 31, 2024 |
| S-8 | Employee stock plan registration | Dec 4, 2024 | — |
| 10-Q | Quarterly report | Sep 17, 2024 | Jul 31, 2024 |
| NT 10-Q | Extension | Sep 17, 2024 | Jul 31, 2024 |
| 10-K | Annual report | Aug 13, 2024 | Apr 30, 2024 |
| NT 10-K | Form 12b-25 | Jul 29, 2024 | Apr 30, 2024 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Other events
|
May 23, 2024 | May 20, 2024 |
| 8-K |
Current report
Shareholder vote results
|
May 1, 2024 | Apr 29, 2024 |
| DEF 14A | Proxy statement | Mar 27, 2024 | Apr 29, 2024 |
| ARS | Annual report to shareholders | Mar 27, 2024 | Dec 31, 2023 |
| 10-Q | Quarterly report | Mar 18, 2024 | Jan 31, 2024 |
| 10-Q | Quarterly report | Dec 15, 2023 | Oct 31, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 24, 2023 | Nov 20, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 16, 2023 | Nov 14, 2023 |
| 8-K |
Current report
Auditor change
|
Nov 9, 2023 | Nov 5, 2023 |
| EFFECT | Filing | Sep 29, 2023 | — |
| CORRESP | Letter to the SEC | Sep 27, 2023 | — |
| S-3/A | Filing | Sep 21, 2023 | — |
| 10-Q | Quarterly report | Sep 18, 2023 | Jul 31, 2023 |
| NT 10-Q | Form 12b-25 | Sep 15, 2023 | Jul 31, 2023 |
| S-3/A | Amendment 2 | Sep 12, 2023 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Sep 7, 2023 | Aug 31, 2023 |
| CORRESP | Letter to the SEC | Aug 4, 2023 | — |
| S-3/A | Amendment no. 1 | Aug 4, 2023 | — |
| 8-K |
Current report
Auditor change
|
Aug 4, 2023 | Aug 1, 2023 |
| 10-K | Annual report | Jul 31, 2023 | Apr 30, 2023 |
| DEF 14A | Proxy statement | Jul 31, 2023 | Aug 31, 2023 |
| PRE 14A | Preliminary proxy statement | Jul 19, 2023 | Aug 31, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jul 19, 2023 | Jul 14, 2023 |
| UPLOAD | Letter from the SEC | Jun 26, 2023 | — |
| SC TO-I/A | Filing | Jun 15, 2023 | — |
| S-3 | Shelf registration | Jun 9, 2023 | — |
| DEF 14A | Proxy statement | Jun 5, 2023 | Jun 5, 2023 |
| CORRESP | Letter to the SEC | Jun 5, 2023 | — |
| CORRESP | Letter to the SEC | May 30, 2023 | — |
| PRE 14A | Preliminary proxy statement | May 25, 2023 | Jul 7, 2023 |
| UPLOAD | Letter from the SEC | May 19, 2023 | — |
| SC TO-I | Schedule to-i | May 11, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Shareholder vote results, Other events
|
May 11, 2023 | May 9, 2023 |
| 10-Q | Quarterly report | Mar 16, 2023 | Jan 31, 2023 |
| 8-K |
Current report
Other events
|
Feb 2, 2023 | Jan 31, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Dec 30, 2022 | Dec 28, 2022 |
| 10-Q | Quarterly report | Dec 14, 2022 | Oct 31, 2022 |
| DEF 14A | Proxy statement | Nov 25, 2022 | Dec 28, 2022 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Nov 18, 2022 | Nov 14, 2022 |
| PRE 14A | Preliminary proxy statement | Nov 15, 2022 | Dec 28, 2022 |
| 8-K |
Current report
Officer or director change
|
Nov 7, 2022 | Nov 1, 2022 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 14, 2022 | Oct 10, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 7, 2022 | Oct 6, 2022 |
| 10-Q | Quarterly report | Sep 14, 2022 | Jul 31, 2022 |
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure
|
Aug 16, 2022 | Aug 15, 2022 |
| DEFA14A | Additional proxy material | Aug 16, 2022 | — |
| 10-K | Annual report | Jul 28, 2022 | Apr 30, 2022 |
| 8-K |
Current report
Other events
|
Jul 28, 2022 | Jul 28, 2022 |
| DEFA14A | Additional proxy material | Jul 28, 2022 | — |
| DFAN14A | Filing | Jul 28, 2022 | — |
| PREC14A | Filing | Jul 26, 2022 | — |
| 8-K |
Current report
Other events
|
Jul 21, 2022 | Jul 21, 2022 |
| DEFA14A | Additional proxy material | Jul 21, 2022 | — |
| 8-K |
Current report
Other events
|
Jul 19, 2022 | Jul 19, 2022 |
| DEFA14A | Additional proxy material | Jul 19, 2022 | — |
| DFAN14A | Filing | Jul 11, 2022 | — |
| 8-K |
Current report
Results of operations, Other events
|
Jul 11, 2022 | Jul 11, 2022 |
| DEFA14A | Additional proxy material | Jul 11, 2022 | — |
| DFAN14A | Filing | Jul 5, 2022 | — |
| DFAN14A | Filing | Jun 23, 2022 | — |
| 8-K |
Current report
Other events
|
Jun 15, 2022 | Jun 15, 2022 |
| DEFA14A | Additional proxy material | Jun 15, 2022 | — |
| 8-K |
Current report
Other events
|
Jun 7, 2022 | Jun 1, 2022 |
| 8-K |
Current report
Officer or director change, Other events
|
Apr 13, 2022 | Apr 7, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 5, 2022 | Mar 31, 2022 |
| 10-Q | Quarterly report | Mar 15, 2022 | Jan 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 9, 2022 | Mar 7, 2022 |
| 8-K |
Current report
Listing notice
|
Mar 1, 2022 | Feb 24, 2022 |
| 8-K |
Current report
Listing notice
|
Feb 17, 2022 | Feb 15, 2022 |
| 10-Q | Quarterly report | Dec 14, 2021 | Oct 31, 2021 |
| 424B3 | Prospectus | Nov 22, 2021 | — |
| EFFECT | Filing | Nov 17, 2021 | — |
| CORRESP | Letter to the SEC | Nov 15, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2021 | — |
| S-3 | Shelf registration | Nov 8, 2021 | — |
| 10-Q | Quarterly report | Sep 14, 2021 | Jul 31, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 10, 2021 | Sep 9, 2021 |
| D | Filing | Sep 1, 2021 | — |
| 424B5 | Prospectus supplement | Aug 23, 2021 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Aug 23, 2021 | Aug 19, 2021 |
| S-3MEF | Form s-3 mef | Aug 19, 2021 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 12, 2021 | Aug 9, 2021 |
| CERT | 8a cert | Aug 10, 2021 | — |
| 10-K | Annual report | Aug 10, 2021 | Apr 30, 2021 |
| 424B5 | Prospectus supplement | Aug 10, 2021 | — |
| 8-K |
Current report
Other events
|
Aug 2, 2021 | Aug 2, 2021 |
| 424B5 | Prospectus supplement | Aug 2, 2021 | — |
| 8-A12B | Registration of certain classes of securities | Aug 2, 2021 | — |
| NT 10-K | Notice of late filing | Jul 29, 2021 | Apr 30, 2021 |
| 8-K |
Current report
Other events
|
Jul 13, 2021 | Jul 9, 2021 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jul 6, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Other events
|
Jun 22, 2021 | Jun 18, 2021 |
| 8-K |
Current report
Other events
|
Jun 15, 2021 | Jun 14, 2021 |
| 8-K |
Current report
Other events
|
Jun 4, 2021 | Jun 4, 2021 |
| 8-K |
Current report
Other events
|
May 6, 2021 | May 5, 2021 |
| EFFECT | Filing | Apr 14, 2021 | — |
| CORRESP | Letter to the SEC | Apr 12, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2021 | — |
| S-3 | Shelf registration | Apr 5, 2021 | — |
| 10-Q | Quarterly report | Mar 12, 2021 | Jan 31, 2021 |
| 10-Q | Quarterly report | Dec 11, 2020 | Oct 31, 2020 |
| 8-K |
Current report
Officer or director change
|
Oct 16, 2020 | Oct 14, 2020 |
| 10-Q | Quarterly report | Sep 11, 2020 | Jul 31, 2020 |
| 10-K | Annual report | Aug 13, 2020 | Apr 30, 2020 |
| NT 10-K | Extension | Jul 29, 2020 | Apr 30, 2020 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 8, 2020 | Apr 6, 2020 |
| 10-Q | Quarterly report | Mar 13, 2020 | Jan 31, 2020 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jan 21, 2020 | Jan 21, 2020 |
| 10-Q | Quarterly report | Dec 23, 2019 | Oct 31, 2019 |
| NT 10-Q | Extension | Dec 16, 2019 | Oct 31, 2019 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 8, 2019 | Nov 7, 2019 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 3, 2019 | Sep 20, 2019 |
| 10-Q | Quarterly report | Sep 13, 2019 | Jul 31, 2019 |
| 8-K |
Current report
Other events
|
Aug 26, 2019 | Aug 23, 2019 |
| 10-K | Annual report | Aug 13, 2019 | Apr 30, 2019 |
| NT 10-K | Notice of late filing | Jul 29, 2019 | Apr 30, 2019 |
| 10-Q | Quarterly report | Mar 14, 2019 | Jan 31, 2019 |
| 10-Q | Quarterly report | Dec 14, 2018 | Oct 31, 2018 |
| 10-Q | Quarterly report | Sep 12, 2018 | Jul 31, 2018 |
| 10-K | Annual report | Jul 20, 2018 | Apr 30, 2018 |
| 8-K |
Current report
Material agreement
|
May 15, 2018 | May 14, 2018 |
| 10-Q | Quarterly report | Mar 19, 2018 | Jan 31, 2018 |
| 424B5 | Prospectus supplement | Feb 22, 2018 | — |
| 8-K |
Current report
Material agreement, Agreement ended
|
Feb 22, 2018 | Feb 22, 2018 |
| 10-Q | Quarterly report | Dec 14, 2017 | Oct 31, 2017 |
| UPLOAD | Letter from the SEC | Nov 6, 2017 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 10, 2017 | Oct 10, 2017 |
| EFFECT | Filing | Sep 28, 2017 | — |
| 424B3 | Prospectus | Sep 28, 2017 | — |
| CORRESP | Letter to the SEC | Sep 26, 2017 | — |
| S-3 | Shelf registration | Sep 13, 2017 | — |
| 10-Q | Quarterly report | Sep 13, 2017 | Jul 31, 2017 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 6, 2017 | Aug 30, 2017 |
| 10-K | Annual report | Jul 27, 2017 | Apr 30, 2017 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 10, 2017 | Jul 3, 2017 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 2, 2017 | May 1, 2017 |
| 10-Q/A | Amended quarterly report | Mar 13, 2017 | Jan 31, 2017 |
| 10-Q | Quarterly report | Mar 13, 2017 | Jan 31, 2017 |
| 8-K |
Current report
Material agreement
|
Dec 21, 2016 | Dec 15, 2016 |
| 10-Q | Quarterly report | Dec 2, 2016 | Oct 31, 2016 |
| 10-Q | Quarterly report | Sep 6, 2016 | Jul 31, 2016 |
| 10-K | Annual report | Jul 29, 2016 | Apr 30, 2016 |
| NT 10-K | Form 12b-25 (nt 10-k) | Jul 14, 2016 | Apr 30, 2016 |
| 10-Q | Quarterly report | Mar 8, 2016 | Jan 31, 2016 |
| UPLOAD | Letter from the SEC | Mar 3, 2016 | — |
| 10-K/A | Amended annual report | Mar 2, 2016 | Apr 30, 2015 |
| CORRESP | Letter to the SEC | Feb 2, 2016 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2016 | — |
| 10-K/A | Amended annual report | Jan 19, 2016 | Apr 30, 2015 |
| 10-Q/A | Amended quarterly report | Jan 19, 2016 | Oct 31, 2015 |
| D | Filing | Jan 19, 2016 | — |
| 10-Q/A | Amended quarterly report | Jan 19, 2016 | Oct 31, 2015 |
| 10-Q/A | Amended quarterly report | Jan 19, 2016 | Jul 31, 2015 |
| 10-K/A | Amended annual report | Jan 19, 2016 | Apr 30, 2015 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jan 12, 2016 | Jan 7, 2016 |
| 8-K |
Current report
Restatement, Officer or director change
|
Dec 31, 2015 | Dec 30, 2015 |
| 10-Q | Quarterly report | Dec 10, 2015 | Oct 31, 2015 |
| 8-K |
Current report
Auditor change
|
Nov 2, 2015 | Oct 29, 2015 |
| 8-K |
Current report
Officer or director change
|
Oct 2, 2015 | Sep 28, 2015 |
| 10-Q | Quarterly report | Aug 25, 2015 | Jul 31, 2015 |
| 10-K | Annual report | Jul 29, 2015 | Apr 30, 2015 |
| NT 10-K | Notice of late filing | Jul 14, 2015 | Apr 30, 2015 |
| 8-K |
Current report
Auditor change
|
May 28, 2015 | May 26, 2015 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PMCB (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1157075
- Former names
- NUVILEX, INC. (until Jan 9, 2015); EFOODSAFETY COM INC (until Mar 17, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.